|
(Alliance News) - AstraZeneca PLC on Thursday said its Alexion subsidiary has reached a settlement agreement with Roche Holding AG's Chugai Pharmaceutical Co Ltd resolving all patent disputes between the two related to rare blood disease drug Ultomiris.
Alexion will make a single payment of $775 million in the second quarter of 2022. AstraZeneca said the settlement will not impact its full-year financial guidance.
The two have taken steps to withdraw patent infringement proceedings filed with US District Court for the District of Delaware and Tokyo District Court.
‘With this settlement, we will continue to advance our Ultomiris development programmes in new indications and focus on our mission to transform the lives of people affected by rare diseases,’ said Alexion Chief Executive Marc Dunoyer.
AstraZeneca completed its $39 billion takeover of Boston-based rare diseases firm Alexion Pharmaceuticals Inc in July last year.
By Lucy Heming; lucyheming@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
